Featured News
Adds Proven Kidney-on-Chip Technology to Its Pioneering Bio-AI Platform
Companies Extend Collaboration After Successful Preclinical Study Assessed the Quris-AI BioAI Drug Safety Platform
Through the technology and expertise, Quris-AI is tackling the most impactful challenge of our time: Predicting which drug candidates will safely work in humans.
AI innovator disrupting the pharmaceutical industry joins the ranks of Microsoft, Apple, Novartis, and more
New technology involving miniature human organs built in a lab is a step towards better treatments and ending a contentious practice.
New technology involving miniature human organs built in a lab is a step towards better treatments and ending a contentious practice.
With a platform that can predict which drug candidates will work in humans—and eliminate the costly and inefficient practice of testing on animals—Quris hopes to revolutionize drug development.
Quris expands Seed funding to $37 million with latest $9 million investment led by SoftBank Vision Fund 2, alongside existing private and institutional investors, strengthening momentum to close drug development gaps.
Six startup companies have been selected to participate in the BeyondBio SCALE program led by pharmaceutical giant AstraZeneca, Accenture, Amazon Web Services and Clalit - the largest healthcare organization in Israel.
Merck KGaA, Darmstadt, Germany, Enters into Option Agreement with Quris on its BioAI Platform for Clinical Safety Prediction. The agreement between the two companies is exclusive to only one disease for a period of five years.
Led by Welltech Ventures, with participation from iAngels and GlenRock Capital and leading tech pioneers. "We invested in Quris because it has developed a disruptive machine-learning platform that better predicts which drug candidates will safely work in humans." – Dr. Kobi Richter. More...
Quris Launches First AI Clinical Prediction Platform
A disruptive bio-AI platform that combines cutting-edge machine-learning, together with miniaturized Patients-on-a-Chip to predict drug safety and efficacy.
Moderna Co-founder Robert Langer Joins Quris’ SAB
“We are at the tipping point of modernization of drug discovery. I think the Quris platform could be of significant value to pharma companies" – Prof. Robert Langer
Exclusive Collaboration With NYSCF, World Leader in Stem Cell Automation
“We are at the cusp of a paradigm shift in drug testing and development. Our team of scientists is excited about the collaboration with Quris." Watch NYSCF's TED TALK
as featured on:
_svg.png){kind=logo}
.png){kind=small}